Akums Drugs and Pharmaceuticals Limited has informed the Exchange regarding Appointment of Mr Anil Kumar Arvindlal Amin as Non- Executive Independent Director of the company w.e.f. Jun 04, 2025.
AKUMS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Akums Drugs and Pharmaceuticals has appointed Mr. Anil Kumar Arvindlal Amin (DIN: 10594012) as an Additional Director (Non-Executive Independent) with effect from June 04, 2025, for a five-year term, pending shareholder approval at the upcoming AGM. Mr. Amin brings over 30 years of pharmaceutical industry experience, most recently serving as the Chief Business Development Officer at Viatris, where he led strategic partnerships, M&A, and divestments. He previously held senior roles at Mylan and spent 20 years at Pfizer, and holds a master's degree in technology management from the New Jersey Institute of Technology. He is not related to any existing directors on the board and is not debarred by SEBI or any other authority.
This is a routine board strengthening move that adds a globally experienced pharma industry veteran to Akums' board. The appointment is subject to shareholder approval and is unlikely to have an immediate material impact on the stock price, though it may enhance governance and strategic oversight.